GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Santhera Pharmaceuticals Holding AG (LTS:0QN1) » Definitions » ROIC %

Santhera Pharmaceuticals Holding AG (LTS:0QN1) ROIC % : -31.89% (As of Jun. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Santhera Pharmaceuticals Holding AG ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Santhera Pharmaceuticals Holding AG's annualized return on invested capital (ROIC %) for the quarter that ended in Jun. 2024 was -31.89%.

As of today (2024-12-15), Santhera Pharmaceuticals Holding AG's WACC % is 3.70%. Santhera Pharmaceuticals Holding AG's ROIC % is 46.41% (calculated using TTM income statement data). Santhera Pharmaceuticals Holding AG generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Santhera Pharmaceuticals Holding AG ROIC % Historical Data

The historical data trend for Santhera Pharmaceuticals Holding AG's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santhera Pharmaceuticals Holding AG ROIC % Chart

Santhera Pharmaceuticals Holding AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.70 -61.55 -61.20 -54.04 48.28

Santhera Pharmaceuticals Holding AG Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -54.03 -53.33 -36.82 122.39 -31.89

Competitive Comparison of Santhera Pharmaceuticals Holding AG's ROIC %

For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santhera Pharmaceuticals Holding AG's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's ROIC % distribution charts can be found below:

* The bar in red indicates where Santhera Pharmaceuticals Holding AG's ROIC % falls into.



Santhera Pharmaceuticals Holding AG ROIC % Calculation

Santhera Pharmaceuticals Holding AG's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=51.161 * ( 1 - 0.07% )/( (99.191 + 112.613)/ 2 )
=51.1251873/105.902
=48.28 %

where

Santhera Pharmaceuticals Holding AG's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Jun. 2024 is calculated as:

ROIC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-35.482 * ( 1 - -1.15% )/( (112.613 + 112.476)/ 2 )
=-35.890043/112.5445
=-31.89 %

where

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Santhera Pharmaceuticals Holding AG  (LTS:0QN1) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Santhera Pharmaceuticals Holding AG's WACC % is 3.70%. Santhera Pharmaceuticals Holding AG's ROIC % is 46.41% (calculated using TTM income statement data). Santhera Pharmaceuticals Holding AG generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases. Santhera Pharmaceuticals Holding AG earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Santhera Pharmaceuticals Holding AG ROIC % Related Terms

Thank you for viewing the detailed overview of Santhera Pharmaceuticals Holding AG's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Santhera Pharmaceuticals Holding AG Business Description

Traded in Other Exchanges
Address
Hohenrainstrasse 24, Pratteln, CHE, 4133
Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, an area that includes many orphan and niche indications with high unmet medical needs. It has one operating segment, namely the development and commercialization of products for the treatment of neuro-ophthalmological, pulmonary, and neuromuscular diseases. The company derives the majority of its revenue from the European Union.

Santhera Pharmaceuticals Holding AG Headlines

No Headlines